Cyancare Therapeutics India Private Limited
Founded in 2015 and headquartered in Uttarakhand, India.
2015 | Haridwar, Uttarakhand (India) | Active
Cyancare Therapeutics India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -32.57%
- Profit Growth -18.41%
- Ebitda -87.18%
- Net Worth 46.29%
- Total Assets 124.25%
About Cyancare Therapeutics India
Cyancare Therapeutics India Private Limited (CTIPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 March 2015 (Nine years and 11 months 13 days old ). Its registered office is in Haridwar, Uttarakhand, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Swadesh Barnwal, Rakesh Barnwal, Satyendra Rai, and One other member serve as directors at the Company.
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24297UR2015PTC001444
- Company No.
001444
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Healthcare
Who are the key members and board of directors at Cyancare Therapeutics India?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swadesh Barnwal  | Director | 16-Mar-2015 | Current |
| Rakesh Barnwal | Director | 16-Mar-2015 | Current |
| Satyendra Rai | Director | 10-Apr-2015 | Current |
| Durgeshwar Tiwari | Director | 10-Apr-2015 | Current |
Financial Performance of Cyancare Therapeutics India.
Cyancare Therapeutics India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 32.57% decrease. The company also saw a substantial fall in profitability, with a 18.41% decrease in profit. The company's net worth Soared by an impressive increase of 46.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyancare Therapeutics India?
In 2017, Cyancare Therapeutics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cyancare Therapeutics India?
Unlock and access historical data on people associated with Cyancare Therapeutics India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyancare Therapeutics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyancare Therapeutics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.